We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
Neocure prevents 30,000 children from going blind each year due to ROP using AI technology. ROP can be treated, but it is often hard to find in time. Our AI analyzes the risk for each baby, helping to prevent missed diagnoses in hospitals where there aren't enough eye specialists. By helping doctors focus on the most urgent cases, we can stop blindness caused by ROP.
Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.
A startup combining genome editing with smart land-based aquaculture to breed and produce high-value fish species using local resources. It aims to revitalize the fisheries industry and stabilize food supply, while contributing to lower environmental impact and regional revitalization.